The impact of outpatient vs inpatient management on health-related quality of life outcomes for patients with malignant pleural effusion - the OPTIMUM randomized clinical trial.
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
received:
14
06
2022
accepted:
21
10
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
aheadofprint
Résumé
The principal aim of malignant pleural effusion (MPE) management is to improve health related quality of life (HRQoL) and symptoms. In this open-label randomised controlled trial, patients with symptomatic MPE were randomly assigned to either IPC insertion with the option of talc pleurodesis or chest drain and talc pleurodesis. The primary endpoint was global health status, measured with the EORTC QLQ-C30 questionnaire at 30 days post-intervention. 142 participants were enrolled from July 2015 to December 2019. Of participants randomly assigned to IPC (n=70) and chest drain (n=72), primary outcome data were available in 58 and 56 patients, respectively. Global health status improved in both groups at day 30 compared to baseline: IPC (mean difference 13.11 p While HRQoL significantly improved in both groups, there were no differences in patient reported global health status at 30 days. The outpatient pathway using an IPC was not superior to inpatient treatment with a chest drain. ISRCTN registration:15503522.
Sections du résumé
BACKGROUND
BACKGROUND
The principal aim of malignant pleural effusion (MPE) management is to improve health related quality of life (HRQoL) and symptoms.
METHODS
METHODS
In this open-label randomised controlled trial, patients with symptomatic MPE were randomly assigned to either IPC insertion with the option of talc pleurodesis or chest drain and talc pleurodesis. The primary endpoint was global health status, measured with the EORTC QLQ-C30 questionnaire at 30 days post-intervention. 142 participants were enrolled from July 2015 to December 2019.
RESULTS
RESULTS
Of participants randomly assigned to IPC (n=70) and chest drain (n=72), primary outcome data were available in 58 and 56 patients, respectively. Global health status improved in both groups at day 30 compared to baseline: IPC (mean difference 13.11 p
CONCLUSION
CONCLUSIONS
While HRQoL significantly improved in both groups, there were no differences in patient reported global health status at 30 days. The outpatient pathway using an IPC was not superior to inpatient treatment with a chest drain.
TRIAL REGISTRATION
BACKGROUND
ISRCTN registration:15503522.
Identifiants
pubmed: 37996243
pii: 13993003.01215-2022
doi: 10.1183/13993003.01215-2022
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©The authors 2023. For reproduction rights and permissions contact permissions@ersnet.org.